Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy

NCT07151326 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

National Health Research Institutes, Taiwan

Collaborators